Advertisement
Canada markets closed

  • S&P/TSX

    24,471.17
    +168.91 (+0.70%)
     

  • S&P 500

    5,815.03
    +34.98 (+0.61%)
     

  • DOW

    42,863.86
    +409.74 (+0.97%)
     

  • CAD/USD

    0.7266
    -0.0011 (-0.16%)
     

  • CRUDE OIL

    75.49
    -0.36 (-0.47%)
     

  • Bitcoin CAD

    86,938.42
    +204.33 (+0.24%)
     

  • XRP CAD

    0.74
    -0.00 (-0.34%)
     

  • GOLD FUTURES

    2,674.20
    +34.90 (+1.32%)
     

  • RUSSELL 2000

    2,234.41
    +45.99 (+2.10%)
     

  • 10-Yr Bond

    4.0730
    -0.0230 (-0.56%)
     

  • NASDAQ

    18,342.94
    +60.89 (+0.33%)
     

  • VOLATILITY

    20.46
    -0.47 (-2.25%)
     

  • FTSE

    8,253.65
    +15.92 (+0.19%)
     

  • NIKKEI 225

    39,605.80
    +224.91 (+0.57%)
     

  • CAD/EUR

    0.6642
    -0.0011 (-0.17%)
     

BioCryst to Report First Quarter 2023 Financial Results on May 3

BioCryst Pharmaceuticals, Inc.
Updated ·1 min read
BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc.

RESEARCH TRIANGLE PARK, N.C., April 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2023 financial results on Wednesday, May 3, 2023.

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 1-866-777-2509 for domestic callers and 1-412-317-5413 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States and many global markets. BioCryst has active programs to develop oral medicines for multiple targets across the complement system, including BCX10013, an oral Factor D inhibitor in clinical development. RAPIVAB® (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW

Investor Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com